Why Sarepta’s Gene Therapy Trial Enrollment Has Been More Successful Than Its Other DMD Therapies

The EMBARK trial’s availability to more patients likely contributed to the much quicker enrollment than confirmatory trials for Exondys 51, Vyondys 53 and Amondys 45, which also saw enrollment targets and eligibility ages change over the years.